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Background: Psoriasis is no longer viewed as an isolated dermatological ailment and instead is considered a systemic
disease. The extension of this spectrum has heightened the known risk of morbidity and mortality due to the
involvement of cardiovascular system and the risk of venous thrombosis. A number of cases have reported the
increased occurrence of deep vein thrombosis and pulmonary embolism in the background of psoriasis, however
portal vein thrombosis has not been reported to date. We report an index case of chronic portal vein thrombosis
in a diagnosed patient with psoriasis.
Case presentation: A 67-year-old South-Asian female previously diagnosed and treated for psoriasis presented
with a four month history of abdominal pain associated with abdominal distension. Clinical examination revealed
an enlarged spleen and free fluid in the abdomen. Imaging with ultrasonography and computed tomography of
the abdomen revealed features compatible with chronic portal vein thrombosis with cavernous transformation.
Conclusion: This case highlights the importance of having clinical awareness of occurrence of thrombosis in
patients with psoriasis. Typical symptoms favoring thrombosis should prompt thorough investigation to exclude
this rare yet possible complication in patients with psoriasis, including that of portal vein thrombosis. Prophylaxis
with anticoagulation still lacks strength of evidence to be justified in psoriasis. The exact pathogenesis of venous
thromboembolism in psoriasis is still unexplained and further studies are needed to clarify the causal association.
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Psoriasis is an inflammatory disease affecting 2% of the
population [1,2]. The disease is no longer considered
one that solely afflicts the skin, and with the available
mounting scientific evidence the true systemic nature of
the disease is becoming apparent. The impact of psoriasis is
so expansive it can involve the lungs, kidneys, cardiovascu-
lar system, and also be associated with other autoimmune
conditions, metabolic syndrome and even malignancy [3].
The impact of the Th1 inflammatory defect in psoriasis
extends beyond afflicting the skin and joints and involves
the endothelium as well [4]. A cohort study conducted by
Ahlehoff et al., in Denmark demonstrated age- and sever-
ity dependent increase in risk of cardiovascular and all-
cause mortality in psoriasis patients [5]. Furthermore,
patients with psoriasis also tend to have a higher overall* Correspondence: yudhishdran@yahoo.com
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unless otherwise stated.rate of venous thrombo-embolism (VTE) events than
controls [6,7]. However data pertaining to this is limited,
as is the understanding to its possible pathophysiological
mechanisms. An extensive search of literature revealed
only a few reported cases of VTE occurring with psoriasis,
involving that of the inferior vena cava, deep veins of the
lower limbs, pulmonary vasculature, cerebral venous sinus
and the central retinal vein [8-11]. We report a unique
case of portal vein thrombosis in a patient with psoriasis.
Case presentation
A 67-year-old South-Asian female who had been previ-
ously diagnosed with plaque psoriasis for the last 5 years
and on topical treatment with emollient agents, coal tar
salicylic shampoo and betamethasone cream presented
with a complaint of abdominal distension associated
with abdominal pain of four months duration in the ab-
sence of altered bowel habits. Her history was otherwise
unremarkable and she denied any alcohol consumption,
history of blood transfusion or sexual promiscuity andntral. This is an Open Access article distributed under the terms of the Creative
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cluding the use of indigenous medication. There was also
no history of neonatal umbilical vein cannulation and she
denied any abdominal surgery or trauma.
General examination revealed well defined psoriatic
plaque lesions on the forearms, elbows and in the scalp
associated with scaling. The nails demonstrated dystrophy
with pitting. Clinically she was found to be pale, but she
had no lymphadenopathy, stigmata of liver disease or ankle
oedema. Abdominal examination revealed ascites with
shifting dullness and a firm, non- tender spleen extending
4 cm below the costal margin. Cardiovascular, respiratory,
and nervous system examinations were unremarkable.
Whole blood analysis revealed a mild anemia with a
haemoglobin of 9.8 g/dl (11–18) with a mean corpuscular
volume of 88 fl (80–100). The white cell count was normal
at 6.7 × 109/L (4–10) with 69% neutrophils and 29%
lymphocytes, and the platelet count was reduced at 52×
109/L (150–450). Blood picture mirrored the whole
blood findings and demonstrated a bicytopenia with a
normocytic normochromic anemia and a moderate
thrombocytopenia. Liver functions were within normal
reference range. Aspartate amino-transaminase was at
20 IU/L (10–35) and alanine amino-transaminase was
at 36 IU/L (10–40) while alkaline phosphatase levels were
normal at 200 IU/L. Total serum protein was normal with
a serum albumin of 36 g/L (36–48). Coagulation profile
was normal. Imaging of the abdomen with an ultrasound
scan confirmed a moderately enlarged spleen with the
presence of varices, and thrombosis of the portal vein with
cavernous transformation. A contrast enhanced computed
tomography of the abdomen demonstrated multiple tortu-
ous veins at the porta-hepatis, with an enlarged spleen
and abnormally dilated tortuous vessels draining into the
left renal vein with a normal sized liver with normal archi-
tecture. An upper gastrointestinal endoscopy showed early
oesophageal varices. The radiological diagnosis was that of
chronic portal vein thrombosis with cavernous transform-
ation and a spleno-renal shunt.
The erythrocyte sedimentation rate(ESR) was elevated
at 58 mm (0–15) for the 1st hour, and the C-reactive pro-
tein(CRP) was minimally elevated at 8 mg/dl (<5). The anti-
nuclear antibody titres were normal. Anti-phospholipid
antibody screening demonstrated a strongly positive beta
2 glycoprotein level with negative lupus anticoagulant and
anti-cardiolipin antibodies. The beta 2 glycoprotein level
was repeated after three months and was found to be posi-
tive. Thrombophilic screening for inherited prothrombotic
states demonstrated normal antithrombin III, activated
protein-C, protein-S levels and an undetectable factor V
Leiden mutation. Bone marrow biopsy revealed only a
moderately hyper cellular marrow with active megakaryo-
cytes and was otherwise normal. Ham test was negative
and JAK 2 mutation was also absent. Screening for occultmalignancy with upper and lower gastrointestinal en-
doscopy, imaging of the chest, and mammogram failed
to yield any positive findings. Retroviral screening was
negative.
Discussion
Portal vein thrombosis (PVT) can be acute, recent or
chronic. Chronic portal vein thrombosis develops in pa-
tients’ whose thrombosis does not spontaneously resolve
and can result in formation of a chronic non-cavernous
thrombosed portal vein or cavernous transformation, as
in our patient. The pathogenesis for PVT can be due to
cirrhosis, local inflammatory lesions, injury to the portal
venous system, malignancy as well as various states po-
tentiating thrombophilia [12]. Venous thrombosis compli-
cating psoriasis has been recorded quite early in medical
literature, though it’s true association with the predom-
inantly skin disease was still disputed at that time by
Bunch et al., [10]. However subsequent observational re-
ports impressed upon the increased incidence of thrombo-
embolic disease seen in psoriasis [13]. A prospective
analysis by Lutsey et al., demonstrated that being diag-
nosed with psoriasis increased the risk of incident ven-
ous thrombosis and embolism by as much as 40% [14].
The pathogenesis is still uncertain, and varied hypoth-
esis and contributing phenomenon have been queried and
linked to the occurrence of VTE in psoriasis. The pro-
posed hypothesis include inflammatory processes either
through genetic modulation via chromosomal coding of
proteins associated with inflammatory proteins or dir-
ectly quantifiable levels of inflammatory markers such
as C-reactive protein(CRP), inflammatory cytokines [14-16]
as precipitating causes of thrombosis or the occurrence of
eosinophilia in psoriasis favoring a pro-thrombotic state
[17], and the change in homocysteine levels either due to
the disease process or its treatment, causing endothelial
and vascular injury and triggering modifications in coagula-
tion through plasmin, thrombomodulin and platelet hyper-
activity and activation resulting in thrombosis [6,11,15,18].
Risk factors that predispose to VTE in psoriasis are also
varied and include, immobility either due to disease process
or other causes [16,17], young age, poor response to treat-
ment [16] and disease severity. But it is noted that even
mild disease may be an adequate risk factor for VTE [14].
Drugs have been associated with causing thrombosis in
psoriasis in the past and have resulted in their discontinu-
ation such as azarabine, an effect again possibly intertwined
with homocysteine levels [19,20], etanercept, an anti-
tumour necrosis factor [21] and acitretin, a retinoid
[22]. Efalizumab, an anti-monoclonal antibody which
blocks T-cell functionality and infliximab a chimeric
monoclonal antibody targeting TNF-α [8,23] were also
thought to result in thrombosis when used in psoriasis.
Methotrexate has been purported to possibly have a
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ties [24] though simultaneously it could also cause a
thrombotic event due to its dysregulation of homo-
cysteine levels [6]. Our patient had none of these risk
factors, as her disease was mild and she was on topical
treatment with emollients, steroid and coal tar shampoo.
Her CRP was not elevated though her ESR was elevated.
Her beta 2 glycoprotein was repeatedly positive and
maybe a causative phenomenon as it could signify sec-
ondary anti-phospholipid syndrome(APS) to that of the
autoimmune psoriatic disease, as the association is
noted [25]. Cassano et al., queried the same association
but their analysis failed to reveal significant findings,
though one subject with psoriasis was found to have
anti-phospholipid antibodies [26], but Saigal et al., states
the occurrence of anti-phospholipid antibodies can be
high as 28% in psoriatic patients [27]. The occurrence of
positive anti-phospholipid antibodies can be incidental or
can be an aetiological factor for thrombosis formation in
our patient. But the moderately elevated ESR and clinical
picture favored the background psoriatic disease as the
cause and the low platelets was most likely due to splenic
pooling of platelets than that of findings favoring anti-
phospholipid syndrome.
In psoriatic patients, the occurrence of new onset typical
but non-specific symptoms of venous thrombo-embolism
such as chest pain, shortness of breath, oedema, sudden
onset headache, vision impairment should raise the suspi-
cion of possible VTE [11] as pulmonary embolism [13], in-
ferior vena caval occlusion [10], deep vein thrombosis of
lower limbs, cerebral venous thrombosis [9] and central
retinal vein occlusion [8] could be the underlying causes
for these symptoms. Similarly abdominal pain and swell-
ing in a psoriatic patient could point toward the consider-
ation of a rare yet probable occurrence of portal vein
thrombosis as in our case report. Though psoriasis is now
recognized to be associated with VTE it is still an uncom-
mon occurrence, and this may have led to the delay in
both presentation and diagnosis.
Treatment of venous thrombosis is through anticoagu-
lation, however the possibility of increased risk in psoria-
sis raises the concern whether prophylactic utilization of
warfarin is warranted [11]. The opinion for this is divided
and there is still no clear consensus, but Lutsey et al., con-
cluded as the overall incidence is low VTE preventive
therapy is unjustifiable [14]. Utilization of other possible
therapeutic agents such as methotrexate was clinically un-
warranted in our patient. Additionally when considering
its side effect profile and risk-benefit ratio in consideration
to its association with causing VTE makes it unsuitable.
Even in other commoner clinical situations such as
systemic lupus erythematosus, anticoagulation in the
presence of positive anti-phospholipid antibodies in isola-
tion without thrombosis is not recommended. The lack ofclear consensus and the rarity of the clinical situation with
little or no guidance will probably result in the clinician
concurring with the general agreement of choosing not
to prophylactically treat the possible risk of VTE, though
it could potentially be fatal. The question arises as to
whether occurrence of thrombosis in our patient was
due to the associated pathophysiological mechanisms
associated with psoriasis or true secondary anti-phospholipid
syndrome to that of psoriasis. Additionally there is no
clear role for anticoagulation with warfarin in a patient
who has already developed cavernous transformation
following portal vein thrombosis as the risk of bleeding
in presence of varices discourages its utilization. With
life-long warfarin therapy as the alternate choice and in
consideration of the risks, we chose to defer instituting
anticoagulation as prophylactic treatment.
Conclusion
Though the pathogenesis is not fully understood, the
risk of thrombosis in patients with psoriasis should be
appreciated. Clinicians should be wary of the different
ways in which venous thromboembolism can present in
psoriasis and should have a high index of clinical suspi-
cion when patients present with typical symptoms. Role
of anticoagulants in prophylaxis appears unwarranted
due to risks, lack of strong clinical evidence and definitive
guidance. Screening patients with psoriasis for additional
risk factors that promote thrombosis should be consid-
ered. We report this as an index case of portal vein throm-
bosis in a patient with psoriasis with anti-phospholipid
syndrome.
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